latest news releases from the newsroom
Avigen Granted AV411 Patent for Neuropathic Pain
ALAMEDA, Calif., May 20, 2009 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN) a biopharmaceutical company, announced today that it has been granted United States Patent No. 7,534,806, entitled "Method for Treating Neuropathic Pain and Associated Syndromes." The patent covers the treatment of neuropathic pain with therapeutic doses of AV411 (ibudilast), including syndromes like diabetic neuropathy, post-herpetic neuralgia, and fibromyalgia, and neuropathic pain associated with stroke or accompanying cancer chemotherapy. Avigen anticipates additional patents will be issued covering indications that include addiction, delirium, and psychotic disorders, as well as composition of matter claims on AV411 analogs. AV411 is marketed in Japan but not approved for any indication in the United States.
Melco Crown Entertainment Limited
Melco Crown Entertainment Announces First Quarter 2009 Earnings
NEW YORK, May 20, 2009 (GLOBE NEWSWIRE) -- Melco Crown Entertainment Limited (Nasdaq:MPEL), a developer and owner of casino gaming and entertainment resort facilities focused on the Macau market, today reported its unaudited financial results for the first quarter ending March 31, 2009.